About Transplant Genomics
Transplant Genomics is a company based in Los Angeles (United States) founded in 2013 was acquired by Eurofins Scientific in June 2019. It operates as a HealthTech. Transplant Genomics has raised $20.6 million across 7 funding rounds from investors including Eurofins Scientific. Transplant Genomics offers products and services including TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA. Transplant Genomics operates in a competitive market with competitors including MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Oxford Immunotec, among others.
- Headquarter Los Angeles, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eurofins Transplant Genomics
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.6 M (USD)
in 7 rounds
-
Latest Funding Round
$7.98 M (USD), Series A
Aug 24, 2018
- Investors
-
Employee Count
Not available
-
Acquired by
Eurofins Scientific
(Jun 25, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Transplant Genomics
Transplant Genomics offers a comprehensive portfolio of products and services, including TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA.
Surveillance for subclinical acute rejection in kidneys is provided.
Immunosuppression optimization for liver transplant patients is offered.
Clinical acute rejection detection in kidneys is facilitated.
People of Transplant Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Transplant Genomics
Transplant Genomics has successfully raised a total of $20.6M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $7.98 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Transplant Genomics
Transplant Genomics has secured backing from 1 investor. Prominent investors backing the company include Eurofins Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Laboratory testing and contract research services are provided globally.
|
Locked | Locked | Locked |
Investor details for Transplant Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Transplant Genomics
Investment portfolio details for Transplant Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Transplant Genomics
Detailed financials for Transplant Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Transplant Genomics Comparisons
Peer comparison for Transplant Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Transplant Genomics
Transplant Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Oxford Immunotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
|
| Locked | Locked | Locked |
Immune markers are utilized by Oxford Immunotec for disease diagnostics.
|
|
| Locked | Locked | Locked |
Personalized cancer diagnostics are developed using genomic big data analysis.
|
Detailed competitors of Transplant Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Transplant Genomics
Complete news archive for Transplant Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transplant Genomics
Transplant Genomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Transplant Genomics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Stanley Rose is the current CEO of Transplant Genomics.
Transplant Genomics is a funded company, having raised a total of $20.6M across 7 funding rounds to date.
Molecular diagnostic tests are provided by Eurofins Transplant Genomics to improve organ transplant outcomes. Early signs of graft injury are detected, actionable causes are differentiated, and therapy optimization is enabled. Focus is placed on kidney and liver transplantation with tests like TruGraf Kidney and OmniGraf Liver. The healthcare sector, specifically biotechnology and molecular diagnostics, is served through genetic biomarker-guided solutions.
Transplant Genomics's top competitors include Foundation Medicine, MedGenome and Personalis.
Transplant Genomics offers TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA.
Transplant Genomics has 1 investor. Key investors include Eurofins Scientific.